A Randomized, Open-label, Single Dose, 2x4 Crossover Study to Evaluate the Safety and Pharmacokinetic Characteristics After Co-administration of JW0101 and C2101 and Administration of JW0102 in Healthy Volunteers Under Fasting Conditions
Latest Information Update: 17 Apr 2024
At a glance
- Drugs JW 0101+C 2101 (Primary) ; JW 0102 (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors JW Pharmaceutical
- 17 Apr 2024 New trial record